Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Advanced Medical Solutions ( (GB:AMS) ) has issued an announcement.
Advanced Medical Solutions Group expects to report 2025 revenues of about £228.5 million, up from £177.5 million a year earlier, and EBITDA of £49.5–£50 million, with the board confident of meeting market expectations. Growth was driven by strong performance in key surgical product categories and a recovery in its woundcare business, which offset destocking pressures in the Peters Surgical B2B segment, while integration of the Peters Surgical and Syntacoll acquisitions is progressing as planned and commercial synergies are already contributing, with operational benefits targeted from 2027. Management highlighted that the group’s portfolio is broader and stronger than ever, its geographic footprint has been expanded by the Peters Surgical deal, and plans for deeper penetration into the U.S. market are well advanced, underpinning confidence in another robust year in 2026 and supporting AMS’s positioning for scalable growth, margin improvement and long-term value creation.
The most recent analyst rating on (GB:AMS) stock is a Hold with a £247.00 price target. To see the full list of analyst forecasts on Advanced Medical Solutions stock, see the GB:AMS Stock Forecast page.
Spark’s Take on GB:AMS Stock
According to Spark, TipRanks’ AI Analyst, GB:AMS is a Neutral.
Advanced Medical Solutions shows strong revenue growth and a solid capital structure, but faces challenges with declining profitability margins. Technical indicators suggest a positive trend, though valuation metrics indicate potential overvaluation. Recent corporate events highlight growth potential through strategic acquisitions and investor engagement.
To see Spark’s full report on GB:AMS stock, click here.
More about Advanced Medical Solutions
Advanced Medical Solutions Group is a UK-based medical device company specialising in tissue-healing technologies, including adhesives, sealants, biosurgical devices and sutures. Leveraging advanced material science and applicator design developed in collaboration with surgeons, the group targets global surgical and woundcare markets, with a diversified product and geographic mix and an increasing emphasis on direct sales, particularly following its acquisition of Peters Surgical to accelerate U.S. and international expansion.
Average Trading Volume: 610,149
Technical Sentiment Signal: Buy
Current Market Cap: £476.9M
For a thorough assessment of AMS stock, go to TipRanks’ Stock Analysis page.